Instrument Inactif

Communiqués Revelation Biosciences, Inc. Nasdaq

Actions

REVBU

US76135L2007

Recherche biotechnologique et médicale

Communiqués

21/07	Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
10/07	Revelation Biosciences Announces Adoption of Stockholder Rights Plan	AQ
01/06	Revelation Biosciences Expands Acute Kidney Injury Advisory Board	AQ
11/05	Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders	AQ
07/05	Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026	AQ
06/04	Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board	AQ
30/03	Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study	AQ
24/03	REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference	AQ
19/03	Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference	AQ
08/08/25	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025	BU
24/07/25	Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research	BU
16/07/25	Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study	BU
01/07/25	Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025	BU
29/05/25	Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering	BU
29/05/25	Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering	BU
23/05/25	Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors	BU
08/05/25	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025	BU
29/04/25	Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients	BU
17/03/25	Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells	BU
13/03/25	Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference	BU
06/03/25	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024	BU
26/02/25	Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients	BU
24/02/25	Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval	BU
24/01/25	Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025	BU
21/01/25	Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients	BU